Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
185750.KS
Top 10 Correlated ETFs
185750.KS
Top 10 Correlated Stocks
185750.KS
Financial details
Company Rating
Strong Buy
Market Cap
917.8B
Income
44.29B
Revenue
1411.51B
Book val./share
18591.74
Cash/share
-
Dividend
1000
Dividend %
1.27%
Employees
2.38K
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
55.76
Forward P/E
-
PEG
-6.81
P/S
1.75
P/B
4.23
P/C
-
P/FCF
-99.5
Quick Ratio
-
Current Ratio
1.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.53K
EPS next Y
-
EPS next Q
-
EPS this Y
-95.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.71%
Revenue last 5Y
8.72%
Revenue Q/Q
7.22%
EPS Q/Q
32.88%
-
-
-
-
SMA20
-8.17%
SMA50
-11.88%
SMA100
-18.38%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
8%
ROC
0.13%
Gross Margin
36%
Oper. Margin
7%
Profit Margin
3%
Payout
71%
Shs Outstand
11.68M
Shs Float
7.03M
-
-
-
-
Target Price
-
52W Range
75900.0-120952.38
52W High
-35.02%
52W Low
+3.56%
RSI
34.22
Rel Volume
1.35
Avg Volume
15.6K
Volume
21.12K
Perf Week
-3.91%
Perf Month
-12.96%
Perf Quarter
-16.83%
Perf Half Y
-18.89%
-
-
-
-
Beta
1.33176
-
-
Volatility
1515.5%, 3465.71%
Prev Close
0.77%
Price
78600
Change
1.68%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 77.37K | 88.24K | 99.72K | 120.46K | 12.81K | |
| Net income per share | 4.71K | 3.91K | 4.98K | 8.47K | 407.25 | |
| Operating cash flow per share | 7.15K | 3.93K | 7.14K | 9.64K | 123.01 | |
| Free cash flow per share | 5.28K | 1.66K | 4.84K | 6.24K | -371.22 | |
| Cash per share | 3.98K | 4.24K | 8.53K | 14.96K | 1.79K | |
| Book value per share | 35.14K | 39.56K | 43.75K | 50.98K | 5.4K | |
| Tangible book value per share | 34.03K | 38.34K | 42.41K | 49.23K | 5.2K | |
| Share holders equity per share | 35.14K | 39.56K | 43.75K | 50.98K | 5.4K | |
| Interest debt per share | 9.27K | 9.89K | 11.2K | 12.94K | 2.3K | |
| Market cap | 1356.82B | 1011.03B | 922.8B | 1890.43B | 9682.18B | |
| Enterprise value | 1413.81B | 1069.56B | 963.94B | 1902.91B | 9787.42B | |
| P/E ratio | 25.22 | 23.85 | 17.13 | 20.63 | 226.64 | |
| Price to sales ratio | 1.53 | 1.06 | 0.85 | 1.45 | 7.21 | |
| POCF ratio | 16.61 | 23.72 | 11.94 | 18.12 | 750.33 | |
| PFCF ratio | 22.48 | 56.21 | 17.6 | 28 | -248.64 | |
| P/B Ratio | 3.38 | 2.36 | 1.95 | 3.43 | 17.11 | |
| PTB ratio | 3.38 | 2.36 | 1.95 | 3.43 | 17.11 | |
| EV to sales | 1.6 | 1.12 | 0.89 | 1.46 | 7.28 | |
| Enterprise value over EBITDA | 14.11 | 11.5 | 9.74 | 12.63 | 87.02 | |
| EV to operating cash flow | 17.31 | 25.09 | 12.47 | 18.24 | 758.49 | |
| EV to free cash flow | 23.43 | 59.46 | 18.39 | 28.19 | -251.34 | |
| Earnings yield | 0.04 | 0.04 | 0.06 | 0.05 | 0 | |
| Free cash flow yield | 0.04 | 0.02 | 0.06 | 0.04 | 0 | |
| Debt to equity | 0.05 | 0.11 | 0.05 | 0.1 | 0.24 | |
| Debt to assets | 0.4 | 0.39 | 0.41 | 0.42 | 0.46 | |
| Net debt to EBITDA | 0.57 | 0.63 | 0.42 | 0.08 | 0.94 | |
| Current ratio | 1.64 | 1.91 | 1.7 | 1.87 | 2.08 | |
| Interest coverage | 22.16 | 27.93 | 23.67 | 32.02 | 23.51 | |
| Income quality | 1.52 | 1.01 | 1.43 | 1.14 | 0.3 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Payout ratio | 0.16 | 0.2 | 0.16 | 0.1 | 0.25 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.09 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.26 | -0.58 | -0.32 | -0.35 | -4.02 | |
| Capex to revenue | -0.02 | -0.03 | -0.02 | -0.03 | -0.04 | |
| Capex to depreciation | -0.97 | -1.16 | -1.08 | -1.55 | -1.89 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 61.01K | 59.01K | 70K | 98.57K | 7.03K | |
| ROIC | 0.17 | 0.15 | 0.14 | 0.2 | 0.13 | |
| Return on tangible assets | 0.08 | 0.06 | 0.07 | 0.1 | 0.04 | |
| Graham Net | -15.42K | -15.77K | -14.76K | -12.95K | -1.73K | |
| Working capital | 142.86B | 185.82B | 194.07B | 279.49B | 346.92B | |
| Tangible asset value | 388.96B | 415.52B | 459.04B | 532.56B | 545B | |
| Net current asset value | 92.99B | 109.74B | 144.74B | 205.37B | 186.26B | |
| Invested capital | 0.26 | 0.24 | 0.25 | 0.25 | 0.42 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 107.65B | 106.36B | 123.04B | 144.12B | 136.72B | |
| Average inventory | 144.95B | 156.58B | 167.01B | 185.57B | 205.14B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 49.52 | 43.48 | 55.13 | 64.63 | 55.68 | |
| Days of inventory on hand | 72.58 | 80.88 | 80.27 | 83.22 | 96.76 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 7.37 | 8.39 | 6.62 | 5.65 | 6.55 | |
| Inventory turnover | 5.03 | 4.51 | 4.55 | 4.39 | 3.77 | |
| ROE | 0.13 | 0.1 | 0.11 | 0.17 | 0.08 | |
| Capex per share | -1.87K | -2.27K | -2.3K | -3.4K | -494.23 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 28.96K | 30.32K | 11.52K | 10.86K | 11.65K | |
| Net income per share | 2.12K | 190 | 49.9 | 554.55 | 736.91 | |
| Operating cash flow per share | 2.01K | 921.96 | -816.81 | 204.96 | 888.89 | |
| Free cash flow per share | 786.89 | -77.37 | -1.22K | -155.66 | 615.82 | |
| Cash per share | 12.29K | 20.47K | 5.96K | 0 | 0 | |
| Book value per share | 50.19K | 50.34K | 18.01K | 18K | 18.59K | |
| Tangible book value per share | 48.42K | 48.51K | 17.35K | 18K | 18.57K | |
| Share holders equity per share | 50.19K | 50.34K | 18.01K | 18K | 18.59K | |
| Interest debt per share | 12.17K | 21.14K | 7.59K | -20.25 | -77.98 | |
| Market cap | 1475.49B | 1295.53B | 3487.73B | 3091.83B | 2749.34B | |
| Enterprise value | 1489.79B | 1309.78B | 3592.97B | 3091.83B | 2749.34B | |
| P/E ratio | 15.4 | 151 | 556.06 | 44.36 | 29.68 | |
| Price to sales ratio | 4.5 | 3.79 | 9.64 | 9.06 | 7.51 | |
| POCF ratio | 64.77 | 124.48 | -135.89 | 480.09 | 98.44 | |
| PFCF ratio | 165.81 | -1.48K | -90.81 | -632.14 | 142.09 | |
| P/B Ratio | 2.6 | 2.28 | 6.16 | 5.47 | 4.71 | |
| PTB ratio | 2.6 | 2.28 | 6.16 | 5.47 | 4.71 | |
| EV to sales | 4.55 | 3.83 | 9.93 | 9.06 | 7.51 | |
| Enterprise value over EBITDA | 36.95 | 39.69 | 300.27 | 98.83 | 123.69 | |
| EV to operating cash flow | 65.4 | 125.84 | -139.99 | 480.09 | 98.44 | |
| EV to free cash flow | 167.42 | -1.5K | -93.55 | -632.14 | 142.09 | |
| Earnings yield | 0.02 | 0 | 0 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | -0.01 | 0 | 0.01 | |
| Debt to equity | 0.08 | 0.26 | 0.24 | 0 | 0 | |
| Debt to assets | 0.4 | 0.48 | 0.46 | 0.47 | 0.47 | |
| Net debt to EBITDA | 0.35 | 0.43 | 8.8 | 0 | 0 | |
| Current ratio | 1.86 | 2.07 | 2.08 | 1.99 | 1.87 | |
| Interest coverage | 40.15 | 34.07 | 3.41 | -39.37 | -11 | |
| Income quality | 0.95 | 4.85 | -16.37 | 0.37 | 1.21 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.01 | 0.29 | 0.29 | |
| Research and developement to revenue | 0.12 | 0.1 | 0.14 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0 | 0 | |
| Capex to operating cash flow | -0.61 | -1.08 | 0.5 | -1.76 | -0.31 | |
| Capex to revenue | -0.04 | -0.03 | -0.04 | -0.03 | -0.02 | |
| Capex to depreciation | -2.03 | -1.64 | -1.72 | -1.41 | -1.02 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 48.91K | 14.67K | 4.5K | 14.99K | 17.56K | |
| ROIC | 0.05 | 0.05 | 0.01 | 0.03 | 0.04 | |
| Return on tangible assets | 0.03 | 0 | 0 | 0.02 | 0.02 | |
| Graham Net | -12.44K | -15.08K | -5.77K | -16.01K | -16.35K | |
| Working capital | 268.45B | 366.97B | 346.92B | 340.98B | 329.11B | |
| Tangible asset value | 547.57B | 547.6B | 545B | 0 | 0 | |
| Net current asset value | 201.59B | 195.28B | 186.26B | 180.95B | 193.15B | |
| Invested capital | 0.24 | 0.42 | 0.42 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 59.44 | 57.01 | 49.02 | 0 | 0 | |
| Days of inventory on hand | 91.44 | 94.2 | 85.17 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.51 | 1.58 | 1.84 | 0 | 0 | |
| Inventory turnover | 0.98 | 0.96 | 1.06 | 0 | 0 | |
| ROE | 0.04 | 0 | 0 | 0.03 | 0.04 | |
| Capex per share | -1.23K | -999.33 | -405.5 | -360.62 | -273.07 |
Frequently Asked Questions
What is Chong Kun Dang Pharmaceutical Corp. stock symbol ?
Chong Kun Dang Pharmaceutical Corp. is a US stock and trading under the symbol 185750.KS
What is Chong Kun Dang Pharmaceutical Corp. stock quote today ?
Chong Kun Dang Pharmaceutical Corp. stock price is $78600 today.
Is Chong Kun Dang Pharmaceutical Corp. stock public?
Yes, Chong Kun Dang Pharmaceutical Corp. is a publicly traded company.
Company Profile
- Volume Average 15.6K
- Market Capitalization 917.8B
- Employee 2.38K
- Headquarters Seoul,US
- IPO Date 2013-12-06
-
Website
https://www.ckdpharm.com 
Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
